{"brief_title": "4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency?", "brief_summary": "The purpose of this study is to find out whether 4-PBA will increase the level of AAT in persons with AAT deficiency whether or not they have liver disease.", "detailed_description": "The purpose of this study is to determine whether 4-PBA will significantly increase serum Z AAT levels in AAT-deficient individuals with and without evidence of hepatocellular injury and to assess its effects on liver injury.", "condition": ["Alpha 1-Antitrypsin Deficiency"], "intervention_type": ["Drug"], "intervention_name": ["4-PBA"], "description": ["During the first 3 days of this phase baseline serum AAT levels will be determined. The participants will be then given increased amounts of 4-PBA orally in 6 divided doses (day 4-6, 30 g/day and day 7-9, 40/day"], "arm_group_label": ["4-PBA"], "other_name": ["4-phenyl butyric acid"], "criteria": "Inclusion Criteria: - Age 18-65 - Serum A1-PI levels <11uM an appropriate genetic phenotype/genotype - 5 of 10 subjects must have documented laboratory evidence of liver disease - Willingness to withhold Prolastin therapy for 6 weeks prior to screening and throughout the 4-PBA dosing period (up to 3 months) Exclusion Criteria: - Any cause of liver disease other than Alpha-1 Antitrypsin deficiency - Evidence of advanced liver disease - HIV positive - Use of systemic steroids, ursodeoxycholic acid (Actigall, Urso), or herbs in the prior 6 months", "gender": "All", "minimum_age": "18 Years", "maximum_age": "65 Years", "healthy_volunteers": "No", "keyword": "Liver Disease", "mesh_term": ["Alpha 1-Antitrypsin Deficiency", "Alpha 1-Antitrypsin", "Protein C Inhibitor"], "id": "NCT00067756"}